Declined Humoral Immunity of Kidney Transplant Recipients to SARS-CoV-2 Vaccines

References

• Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi:10.1016/j.ijantimicag.2020.105924
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–734. doi:10.1016/j.cmi.2020.03.026
   PubMed Web of Science ®Google Scholar
• Mahallawi WH. Humoral immune responses in hospitalized COVID-19 patients. Saudi J Biol Sci. 2021;28(7):4055–4061. doi:10.1016/j.sjbs.2021.04.032
   PubMed Web of Science ®Google Scholar
• Zhang G, Nie S, Zhang Z, Zhang Z. Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019. J Infect Dis. 2020;222(2):183–188. doi:10.1093/infdis/jiaa229
   PubMed Web of Science ®Google Scholar
• Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020;71(15):778–785. doi:10.1093/cid/ciaa310
   PubMed Web of Science ®Google Scholar
• Ravanan R, Callaghan CJ, Mumford L, et al. SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: a national cohort study. Am J Transplant. 2020;20(11):3008–3018. doi:10.1111/ajt.16247
   PubMed Web of Science ®Google Scholar
• Voora S, Adey DB. Management of kidney transplant recipients by general nephrologists: core curriculum 2019. Am J Kidney Dis. 2019;73(6):866–879. doi:10.1053/j.ajkd.2019.01.031
   PubMed Web of Science ®Google Scholar
• Hricik DE. Transplant immunology and immunosuppression: core curriculum 2015. Am J Kidney Dis. 2015;65(6):956–966. doi:10.1053/j.ajkd.2015.01.026
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation. 2003;75(8):1341–1346. doi:10.1097/01.Tp.0000062833.14843.4b
   PubMed Web of Science ®Google Scholar
• Muntean A, Lucan M. Immunosuppression in kidney transplantation. Clujul Med. 2013;86(3):177–180.
   PubMedGoogle Scholar
• Eickenberg S, Mickholz E, Jung E, Nofer JR, Pavenstadt HJ, Jacobi AM. Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R110. doi:10.1186/ar3835
   PubMed Web of Science ®Google Scholar
• Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood. 2001;97(6):1817–1822. doi:10.1182/blood.V97.6.1817
   PubMed Web of Science ®Google Scholar
• Rashidi-Alavijeh J, Frey A, Passenberg M, et al. Humoral response to SARS-Cov-2 vaccination in liver transplant recipients–a single-center experience. Vaccines. 2021;9(7). doi:10.3390/vaccines9070738
   Web of Science ®Google Scholar
• Yanis A, Haddadin Z, Spieker AJ, et al. Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls. Transpl Infect Dis. 2022;24(1):e13772. doi:10.1111/tid.13772
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204–2206. doi:10.1001/jama.2021.7489
   PubMed Web of Science ®Google Scholar
• Georgery H, Devresse A, Yombi JC, et al. Disappointing immunization rate after 2 doses of the BNT162b2 vaccine in a Belgian cohort of kidney transplant recipients. Transplantation. 2021;105(12):e283–e284. doi:10.1097/tp.0000000000003861
   PubMed Web of Science ®Google Scholar
• Benotmane I, Gautier-Vargas G, Gallais F, et al. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. Am J Transplant. 2021;21(11):3808–3810. doi:10.1111/ajt.16764
   PubMed Web of Science ®Google Scholar
• Goff RR, Wilk AR, Toll AE, McBride MA, Klassen DK. Navigating the COVID-19 pandemic: initial impacts and responses of the organ procurement and transplantation network in the United States. Am J Transplant. 2021;21(6):2100–2112. doi:10.1111/ajt.16411
   PubMed Web of Science ®Google Scholar
• Qu Z, Oedingen C, Bartling T, Schrem H, Krauth C. Organ procurement and transplantation in Germany during the COVID-19 pandemic. Lancet. 2020;396(10260):1395. doi:10.1016/S0140-6736(20)32213-3
   PubMed Web of Science ®Google Scholar
• Benotmane I, Gautier-Vargas G, Cognard N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. 2021;99(6):1498–1500. doi:10.1016/j.kint.2021.04.005
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325(17):1784–1786. doi:10.1001/jama.2021.4385
   PubMed Web of Science ®Google Scholar
• Korth J, Jahn M, Dorsch O, et al. Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech). Viruses. 2021;13(5):756. doi:10.3390/v13050756
   PubMed Web of Science ®Google Scholar
• Del Bello A, Abravanel F, Marion O, et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2021. doi:10.1111/ajt.16775
   Google Scholar
• Balsby D, Nilsson AC, Petersen I, et al. Humoral immune response following a third SARS-CoV-2 mRNA vaccine dose in solid organ transplant recipients compared with matched controls. Front Immunol. 2022;13:1039245. doi:10.3389/fimmu.2022.1039245
   PubMed Web of Science ®Google Scholar
• Al Jurdi A, Gassen RB, Borges TJ, et al. Non-invasive monitoring for rejection in kidney transplant recipients after SARS-CoV-2 mRNA vaccination. Original research. Front Immunol. 2022;2022:13. doi:10.3389/fimmu.2022.838985
   Google Scholar
• Mahallawi WH, Al-Zalabani AH. The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia. Saudi J Biol Sci. 2021;28(3):1697–1701. doi:10.1016/j.sjbs.2020.12.009
   PubMed Web of Science ®Google Scholar
• Mahallawi WH, Ibrahim NA, Aljohani AS, et al. Assessment of SARS-CoV-2 anti-spike IgG antibody in women and children in Madinah, Saudi Arabia: a single-center study. Int J Environ Res Public Health. 2021;18(19):9971. doi:10.3390/ijerph18199971
   PubMed Web of Science ®Google Scholar
• Ma Q, Liu J, Liu Q, et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(12):e2137257. doi:10.1001/jamanetworkopen.2021.37257
   PubMed Web of Science ®Google Scholar
• Almadhi MA, Abdulrahman A, Sharaf SA, et al. The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19. Int J Infect Dis. 2021;105:656–661. doi:10.1016/j.ijid.2021.02.100
   PubMed Web of Science ®Google Scholar
• Syangtan G, Bista S, Dawadi P, et al. Asymptomatic SARS-CoV-2 carriers: a systematic review and meta-analysis. Systematic review. Front Public Health. 2021;2021:8. doi:10.3389/fpubh.2020.587374
   Google Scholar
• Mahallawi W, Ibrahim N. Unexpected detection of anti-SARS-CoV-2 antibodies before the declaration of the COVID-19 pandemic. Front Med. 2022;9:923715. doi:10.3389/fmed.2022.923715
   Web of Science ®Google Scholar
• Kühn T, Speer C, Morath C, et al. Immune response to COVID-19 mRNA vaccination in previous nonresponder kidney transplant recipients after short-term withdrawal of mycophenolic acid 1 and 3 months after an additional vaccine dose. Transplantation. 2023;107(5):1139–1150. doi:10.1097/tp.0000000000004516
   PubMed Web of Science ®Google Scholar
• Sattler A, Schrezenmeier E, Weber UA, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131(14). doi:10.1172/jci150175
   Web of Science ®Google Scholar
• Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21(8):2719–2726. doi:10.1111/ajt.16615
   PubMed Web of Science ®Google Scholar
• Kantauskaite M, Müller L, Kolb T, et al. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. Am J Transplant. 2022;22(2):634–639. doi:10.1111/ajt.16851
   PubMed Web of Science ®Google Scholar
• Benotmane I, Bruel T, Planas D, Fafi-Kremer S, Schwartz O, Caillard S. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients. Kidney Int. 2022;101(5):1073–1076. doi:10.1016/j.kint.2022.02.011
   PubMed Web of Science ®Google Scholar
• Osmanodja B, Ronicke S, Budde K, et al. Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients. J Clin Med. 2022;11(9):2565. doi:10.3390/jcm11092565
   PubMed Web of Science ®Google Scholar
• Zahradka I, Petr V, Modos I, Magicova M, Dusek L, Viklicky O. Association Between SARS-CoV-2 messenger RNA vaccines and lower infection rates in kidney transplant recipients: a registry-based report. Ann Intern Med. 2022;175(7):961–968. doi:10.7326/m21-2973
   PubMed Web of Science ®Google Scholar
• Salem MM. Pathophysiology of hypertension in renal failure. Semin Nephrol. 2002;22(1):17–26. doi:10.1053/snep.2002.28640
   PubMed Web of Science ®Google Scholar
• Hsu C-Y, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165(8):923–928. doi:10.1001/archinte.165.8.923
   PubMedGoogle Scholar
• Mahallawi WH, Ibrahim NA, Mumena WA. Effectiveness of COVID-19 vaccines in patients under maintenance hemodialysis. Risk Manag Healthc Policy. 2021;14:5081–5088. doi:10.2147/rmhp.S345686
   PubMed Web of Science ®Google Scholar
• Soegiarto G, Wulandari L, Purnomosari D, et al. Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. Vaccine. 2022;40(30):4046–4056. doi:10.1016/j.vaccine.2022.05.059
   PubMed Web of Science ®Google Scholar
• Lustig Y, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999–1009. doi:10.1016/s2213-2600(21)00220-4
   PubMed Web of Science ®Google Scholar
• Watanabe M, Balena A, Tuccinardi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465. doi:10.1002/dmrr.3465
   PubMed Web of Science ®Google Scholar
• Hamaya T, Hatakeyama S, Yoneyama T, et al. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients. Sci Rep. 2022;12(1):5876. doi:10.1038/s41598-022-09897-0
   PubMed Web of Science ®Google Scholar
• Schoot TS, Kerckhoffs APM, Hilbrands LB, van Marum RJ. Immunosuppressive drugs and COVID-19: a review. Front Pharmacol. 2020;11:1333. doi:10.3389/fphar.2020.01333
   PubMed Web of Science ®Google Scholar
• Yahav D, Rahamimov R, Mashraki T, et al. Immune response to third dose BNT162b2 COVID-19 vaccine among kidney transplant recipients-a prospective study. Transpl Int. 2022;35:10204. doi:10.3389/ti.2022.10204
   PubMed Web of Science ®Google Scholar
• Magicova M, Zahradka I, Fialova M, et al. Determinants of immune response to anti–SARS-CoV-2 mRNA vaccines in kidney transplant recipients: a prospective cohort study. Transplantation. 2022;106(4):842–852. doi:10.1097/tp.0000000000004044
   PubMed Web of Science ®Google Scholar
• Cheng H, Peng Z, Si S, et al. Immunogenicity and safety of homologous and heterologous prime-boost immunization with COVID-19 vaccine: systematic review and meta-analysis. Vaccines. 2022;10(5):798. doi:10.3390/vaccines10050798
   Web of Science ®Google Scholar
• Reiter R, Von Blanckenburg P, Mutters R, Thiemer J, Geßner R, Seifart U. Influence of a heterologous (ChAdOx1-nCoV-19/BNT162b2) or homologous (BNT162b2/BNT162b2) vaccination regimen on the antibody and T cell response to a third vaccination with BNT162b2. Vaccines. 2022;10(5):788. doi:10.3390/vaccines10050788
   Web of Science ®Google Scholar
• Thotsiri S, Sittiudomsuk R, Sutharattanapong N, Kantachuvesiri S, Wiwattanathum P. The effect of a booster dose mRNA vaccine on COVID-19 infection in kidney transplant recipients after inactivated or viral vector vaccine immunization. Vaccines. 2022;10(10):1690. doi:10.3390/vaccines10101690
   Web of Science ®Google Scholar
• Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med. 2022;182(2):165–171. doi:10.1001/jamainternmed.2021.7372
   PubMed Web of Science ®Google Scholar